Xiadafil VIP Tabs Recall

On Tuesday, the FDA issued an alert warning consumers not to buy or use Xiadafil VIP Tablets, which are sold as a dietary supplement over the internet for sexual enhancement and to treat erectile dysfunction. The FDA has requested that the manufacturer, SEI Pharmaceuticals, issue a Xiadafil VIP Tabs recall because the tablets contain an undeclared ingredient which could impact the users blood pressure and lead to potentially life-threatening injuries.

Although Xiadafil VIP Tabs are marketed as an “all-natural” product, an FDA chemical analysis found that the tablets contain hydroxyhomosildenafil, which an analog of the active pharmaceutical ingredient in the prescription drug Viagra. The FDA has called Xiadafil VIP an “illegally marketed drug” due to the undeclared ingredient.

“Because these products are labeled as ‘all natural dietary supplements,’ consumers may assume that they are harmless and pose no health risk,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The undeclared ingredient could interact with nitrates found in several prescription medications taken by those with diabetes, high blood pressure, high cholesterol or heart disease. As a side effects of Xiadafil VIP Tabs, users could suffer extremely low blood pressure or other life-threatening problems.

The Xadafil VIP Tab recall applies to bottles containing 8 tablets (lot number 6K029) and blister cards containing two tablets (lot number 6K029-SEI), which carry an expiration date of September 2009 (09/09).



  • (VIP) Viril-Ity-Power Tabs Recall: ED Dietary Supplement — AboutLawsuits.comJune 2, 2008 at 3:06 am

    [...] which contained the same undeclared ingredient. The FDA requested that SEI Pharmaceuticals issue an Xiadafil VIP Tablet Recall, since the dietary supplement could interact with other medications and impact users’ blood [...]

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted today)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted yesterday)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.